New Investment entity

LFI a/s has appointed Mette Kirstine Agger to be responsible for the start-up and operation of of a new investment entity, LFI Life Science Investments. It is the intention to focus broadly on life science and further to direct part of the investment activity more specifically towards companies in areas of possible strategic relevance for H. Lundbeck A/S and ALK-Abelló A/S.

Mette Kirstine Agger comes from a position as CEO of 7TM Pharma A/S and has a com-bined scientific and business background with a broad experience within the business area biotech / life science both in terms of business development, formation of contracts, operating companies and financing. Furthermore, Mette Kirstine Agger has an extensive international network both within the industry and in the financial sector.

LFI a/s is a wholly owned subsidiary of the Lundbeck Foundation. LFI a/s has a number of investments in biotech venture funds as well as a 28 pct. interest in the share capital of
LifeCycle Pharma A/S.


How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020
A 60-year-old’s muscles aren’t old at all
23. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge